News
Jazz orchestrates a $4bn cancer alliance with AbCellera
Jazz Pharma has made a big move into T-cell engagers (TCEs) for solid tumours, via an alliance with Canadian biotech AbCellera.
Oncology
Radiopharma in 2026 & beyond, with ITM's Dr Andrew Cavey
Dr Andrew Cavey, CEO of ITM, discusses current and future radiopharmaceutical trends.
News
Poolbeg expects first data for CRS drug in the summer
A trial to see if Poolbeg's POLB-001 can prevent cytokine release syndrome in multiple myeloma treated with immunotherapy Tecvayli will start soon.
Oncology
ASCO 2026: Powerful evidence for the microbiome in oncology,...
Can the state of someone’s gut microbiome – the balance of good and bad bacteria in their digestive tract – affect their response to cancer immunother
News
Lilly trumpets strong result for Jaypirca in CLL at EHA
New data with Eli Lilly's Jaypirca at EHA 2026 has cemented its place as a second-line therapy for chronic lymphocytic leukaemia.
News
Views & Analysis
Deep Dive
Editor's Picks
Editor's Picks
